NIU’s Global Round-up: Algal DHA approval in the EU, key trends for APAC, and more

By Stephen Daniells

- Last updated on GMT

© Getty Images / scanrail
© Getty Images / scanrail

Related tags omega-3 Infant nutrition Convenience foods

What's happened this week around the Nutra-Verse? Stay on top of things with our weekly round-up of key news from across the globe.


Polaris’s DHA-rich algal oil approved for EU sale

France’s Polaris has received authorization from the Food Safety Authority of Ireland for all market segments for its Omegavie DHA 700 algae Sensory QualitySilver 5.

“We’re proud to offer this innovative product to brands and contract manufacturers globally,”​ said Louis-Marie Martin, vice-president of sales and marketing at Polaris.

“Low in saturated fatty acids, and with an outstanding organoleptic profile, it is ideal for a wide range of applications.

“And thanks to its high DHA content, European customers will now be able to create new formulations and more highly concentrated finished products.”

For more on this, please click HERE​.


UPI teams up with Genomma Lab to promote infant nutrition in Mexico

UP International is partnering with Genomma Lab Internacional to expand infant nutrition options in Mexico.

UPI, which is owned by Group Novalac Nutrition & Health, has granted Genomma Lab the exclusive license to market its Novamil and Novalac infant nutrition products in Mexico.

As part of their collaboration, the products — which are now fully supported by Genomma’s Growth Lab in Mexico — will also be distributed by a new team of medical reps who will be targeting specific infant nutrition specialists, including pediatricians and gastro-pediatricians.

For more on this, please click HERE​.


Key trends for dietary supplements and pharma in APAC

According to Mintel, three key trends for dietary supplements and pharma companies across APAC are foods for special medical purposes (FSMP), functional foods, and ease of convenience.

Michelle Teodoro, senior food science and nutrition analyst at Mintel Food and Drink, told NutraIngredients-Asia that Foods for Special Medical Purposes (FSMP) have been gaining attention from firms.

“Both pharmaceutical and food and drink companies can find themselves out of their comfort zones when it comes to pharma foods, with different barriers to entry.

“Food and drink companies will need to expand their R&D capabilities to enhance their scientific creditability while developing relationships with new types of partners including drug stores and health practitioners,” ​she said.

On convenience, Teodoro noted that speedy effect claims are the fastest growing claims in APAC, while portability and ease-of-use claims, also offer opportunities.

For more on this, please click HERE​.




Related news

Show more

Related products

show more

Related suppliers

Follow us


View more